Insider trades by month
US insider trades, April 2025
The 6,792 open-market buys and sales by US company CEOs, executives and directors filed in April 2025.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Princeton BancorpBPRN | Open-market buy | 25/04/28–25/04/30 | 25/04/30 | 2,000 sh2 trades | $30.22avg. | $60,430 | +2.0% | |
Prosperity BancsharesPB | Open-market sale10b5-1 plan | 25/04/30 | 25/04/30 | 1,100 sh3 trades | $67.20avg. | $73,923 | No record | |
Sunrise Realty TrustSUNS | Open-market buy | 25/04/29–25/04/30 | 25/04/30 | 45,903 sh2 trades | $10.56avg. | $484,558.59 | +1.7% | |
Scott Dunseth MyersDirector | Zentalis PharmaceuticalsZNTL | Open-market buy | 25/04/30 | 25/04/30 | 21,000 sh | $1.40 | $29,400 | +8.1% |
Cynthia O. BoothDirector | First Financial BancorpFFBC | Open-market sale | 25/04/30 | 25/04/30 | 18,609 sh | $22.91 | $426,332.19 | −48.7% |
RootROOT | Open-market sale | 25/04/30 | 25/04/30 | 225,000 sh3 trades | $135.81avg. | $30,557,912.42 | −30.9% | |
Dennis E. Murray Jr.Director | Civista BancsharesCIVB | Open-market sale | 25/04/30 | 25/04/30 | 6,143 sh | $22.25 | $136,681.75 | −26.9% |
Relay TherapeuticsRLAY | Open-market sale | 25/04/28–25/04/30 | 25/04/30 | 14,587 sh2 trades | $3.02avg. | $44,040.48 | −3.6% | |
RootROOT | Open-market sale | 25/04/30 | 25/04/30 | 225,000 sh3 trades | $135.81avg. | $30,557,912.42 | −30.9% | |
Relay TherapeuticsRLAY | Open-market sale | 25/04/28–25/04/30 | 25/04/30 | 31,562 sh2 trades | $3.02avg. | $95,381.3 | −5.1% | |
CarGurusCARG | Open-market sale10b5-1 plan | 25/04/28–25/04/30 | 25/04/30 | 56,499 sh6 trades | $28.33avg. | $1,600,858.27 | No record | |
Michelle R. CassabaumDirector | Ames NationalATLO | Open-market buy | 25/04/30 | 25/04/30 | 122 sh | $17.05 | $2,080.1 | +1.5% |
Gwenn HansenChief Scientific Officer | Nurix TherapeuticsNRIX | Open-market sale | 25/04/30 | 25/04/30 | 3,377 sh | $11.50 | $38,835.5 | −5.2% |
Christine RingChief Legal Officer | Nurix TherapeuticsNRIX | Open-market sale | 25/04/30 | 25/04/30 | 2,894 sh | $11.50 | $33,281 | −7.2% |
Nurix TherapeuticsNRIX | Open-market sale | 25/04/30 | 25/04/30 | 2,438 sh | $11.50 | $28,037 | −5.8% | |
Relay TherapeuticsRLAY | Open-market sale10b5-1 plan | 25/04/28–25/04/30 | 25/04/30 | 19,191 sh4 trades | $3.07avg. | $58,848.64 | −5.1% | |
Michael Alan BellOther | CorningGLW | Open-market sale | 25/04/30 | 25/04/30 | 20,262 sh | $44.06 | $892,743.72 | −100.0% |
Mark Jason Blade Sr.Director | First FinancialTHFF | Open-market buy | 25/04/30 | 25/04/30 | 202 sh | $49.09 | $9,916.18 | +7.0% |
SEE REMARKS | Relay TherapeuticsRLAY | Open-market sale | 25/04/28–25/04/30 | 25/04/30 | 12,103 sh2 trades | $3.02avg. | $36,540.88 | −3.0% |
ShimmickSHIM | Open-market sale10b5-1 plan | 25/04/28–25/04/30 | 25/04/30 | 22,840 sh3 trades | $1.73avg. | $39,495.6 | −0.1% |
Other months
- September 20261,445
- June 202620,298
- May 202614,504
- April 20269,432
- March 202614,721
- February 202610,638
- January 20267,844
- December 202512,093
- November 202511,751
- October 202513,072
- September 202513,090
- August 202514,381
- July 20258,748
- June 202511,426
- May 202511,415
- April 20256,792
- March 202512,399
- February 202510,686
- January 20258,151
- December 202416,069
- November 202416,983
- October 20248,518
- September 202410,511
- August 202414,013
- July 202410,847
- June 202412,704
- May 202412,649
- April 20248,608
- March 202417,622
- February 202413,916
- January 20249,748
- December 202314,239
- November 202312,685
- October 20236,365
- September 20239,845
- August 202312,892
- July 20237,232
- June 202311,204
- May 202313,009
- April 20235,870
- March 202313,084
- February 202311,300
- January 20238,626